LIXTE Biotechnology Holdings Provides Corporate Update

Core Insights - LIXTE Biotechnology Holdings, Inc. has completed two financings, raising a total of $6.5 million, which has allowed the company to regain compliance for continued listing on Nasdaq [1][3] - The company has announced management changes, including the appointment of Geordan Pursglove as Chairman and CEO, and the addition of two new independent board members [1][3] - Recent findings published in the journal Nature validate LIXTE's ongoing clinical trials with its lead compound, LB-100, for treating ovarian and colorectal cancer [1][2][3] Financing Activities - LIXTE completed a private placement with accredited investors, raising approximately $5 million, and a registered direct offering, raising approximately $1.5 million [3] - The proceeds from these financings will be used for general corporate purposes and working capital [3] Management Changes - Geordan Pursglove was appointed as Chairman and CEO in June 2025, succeeding Bas van der Baan, who became President and Chief Scientific Officer [3] - Jason Sawyer and Michael Holloway, MD, joined LIXTE's Board as independent directors in July 2025 [3] Scientific Developments - The publication in Nature highlights that patients with tumors having inactivating mutations in PPP2R1A showed significantly better overall survival when treated with immune checkpoint blockade therapy [2][3] - LIXTE has initiated a new pre-clinical study in collaboration with the Netherlands Cancer Institute to test the efficacy of LB-100 on "initiated" cells carrying mutations found in cancer cells [3] Product Pipeline - LIXTE's lead compound, LB-100, is a first-in-class PP2A inhibitor that is well-tolerated in cancer patients and has the potential to enhance chemotherapy and immunotherapy [4][5] - Clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [5]